These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33739437)

  • 41. Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
    Mattiesing RM; Kramer E; Strijbis EM; Brouwer I; van Schijndel RA; Gentile G; Battaglini M; De Stefano N; Uitdehaag BM; Barkhof F; Vrenken H; Schoonheim MM
    Mult Scler; 2024 Jan; 30(1):44-54. PubMed ID: 38018502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.
    Sastre-Garriga J; Pareto D; Rovira À
    Neuroimaging Clin N Am; 2017 May; 27(2):289-300. PubMed ID: 28391787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis.
    Bermel RA; Bakshi R; Tjoa C; Puli SR; Jacobs L
    Arch Neurol; 2002 Feb; 59(2):275-80. PubMed ID: 11843699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting clinical progression in multiple sclerosis after 6 and 12 years.
    Dekker I; Eijlers AJC; Popescu V; Balk LJ; Vrenken H; Wattjes MP; Uitdehaag BMJ; Killestein J; Geurts JJG; Barkhof F; Schoonheim MM
    Eur J Neurol; 2019 Jun; 26(6):893-902. PubMed ID: 30629788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis.
    Wang X; Zhu Q; Yan Z; Shi Z; Xu Y; Liu Y; Li Y
    Mult Scler Relat Disord; 2023 Jul; 75():104740. PubMed ID: 37146422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Uher T; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Ramasamy D; Zivadinov R; Havrdova E; Kalincik T; Horakova D
    Mult Scler; 2017 Jan; 23(1):51-61. PubMed ID: 27053635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.
    Mattiesing RM; Gentile G; Brouwer I; van Schijndel RA; Uitdehaag BMJ; Twisk JWR; Kappos L; Freedman MS; Comi G; Jack D; De Stefano N; Barkhof F; Battaglini M; Vrenken H
    Neuroimage Clin; 2022; 36():103220. PubMed ID: 36274376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal changes of deep gray matter shape in multiple sclerosis.
    Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
    Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS - A longitudinal correlation study.
    Skorve E; Lundervold AJ; Torkildsen Ø; Riemer F; Grüner R; Myhr KM
    Mult Scler Relat Disord; 2023 Jan; 69():104398. PubMed ID: 36462469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis.
    Cohen AB; Neema M; Arora A; Dell'oglio E; Benedict RH; Tauhid S; Goldberg-Zimring D; Chavarro-Nieto C; Ceccarelli A; Klein JP; Stankiewicz JM; Houtchens MK; Buckle GJ; Alsop DC; Guttmann CR; Bakshi R
    J Neuroimaging; 2012 Apr; 22(2):122-8. PubMed ID: 21447024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.
    Bishop CA; Newbould RD; Lee JS; Honeyfield L; Quest R; Colasanti A; Ali R; Mattoscio M; Cortese A; Nicholas R; Matthews PM; Muraro PA; Waldman AD
    Neuroimage Clin; 2017; 13():9-15. PubMed ID: 27896065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
    Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.
    Thompson AJ; Kermode AG; MacManus DG; Kendall BE; Kingsley DP; Moseley IF; McDonald WI
    BMJ; 1990 Mar; 300(6725):631-4. PubMed ID: 2138923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.
    Uher T; Krasensky J; Vaneckova M; Sobisek L; Seidl Z; Havrdova E; Bergsland N; Dwyer MG; Horakova D; Zivadinov R
    J Neuroimaging; 2017 Nov; 27(6):620-629. PubMed ID: 28464417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.
    Jakimovski D; Gandhi S; Paunkoski I; Bergsland N; Hagemeier J; Ramasamy DP; Hojnacki D; Kolb C; Benedict RHB; Weinstock-Guttman B; Zivadinov R
    Eur J Neurol; 2019 Jan; 26(1):87-e8. PubMed ID: 30103277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö
    J Neurol; 2020 Jan; 267(1):192-202. PubMed ID: 31612322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    Nourbakhsh B; Azevedo C; Maghzi AH; Spain R; Pelletier D; Waubant E
    J Neurol Sci; 2016 Jul; 366():229-233. PubMed ID: 27288812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regional grey matter atrophy in clinically isolated syndromes at presentation.
    Henry RG; Shieh M; Okuda DT; Evangelista A; Gorno-Tempini ML; Pelletier D
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1236-44. PubMed ID: 18469033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.